ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck and Yumanity sign neurodegenerative disease deal

by Lisa M. Jarvis
June 26, 2020 | APPEARED IN VOLUME 98, ISSUE 25

 

Merck & Co. and Yumanity Therapeutics will jointly develop neurodegenerative disease treatments. Their deal, which includes an undisclosed up-front payment, gives Merck access to two preclinical Yumanity programs: an amyotrophic lateral sclerosis treatment and a therapy for frontotemporal lobar dementia. Yumanity launched in 2014 to target the misfolded proteins common in neurodegenerative diseases like Alzheimer’s and Parkinson’s. Last year, the company moved its first drug candidate, for Parkinson’s, into Phase I clinical trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment